tirzepatide for heart failure with preserved ejection fraction and obesity Cost-Effectiveness of the Management of summit trial tirzepatide results In

Semaglutide is the established gold standard with FDA approval, proven cardiovascular benefit, extensive clinical data, and multiple formulation options

Current treatment strategies in PV have not been shown to prolong survival or lessen the risk of leukemic or fibrotic progression and instead are directed at preventing thrombotic complications

61 The (THR) -selective agonists strong ability to reduce hepatic fat and multiple atherogenic lipids (LDL cholesterol, apolipoprotein B, triglycerides, lipoprotein) suggests a possible cardiovascular benefit, which is highly desirable in the NASH population

Just activation of a pathway that already exists from a clinically studied herbal extract

This isnt just anecdotal